MedTrace Logo

Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?

NCT03068520 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2017-03-21

No results posted yet for this study

Summary

PET-MRI scanning regarding amino acid metabolic profile, functional and morphological details will be performed on set intervals to patients with brain tumor \& brain metastases in order to try to optimize the study protocol, distinguish between pseudo-response to anti-angiogenic therapy and tumor progression, and most importantly try to distinguish between progressive tumor and treatment related effects.3 cohort of patients will be included in the study.

Conditions

Interventions

DIAGNOSTIC_TEST

PET MR

PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals

Sponsors & Collaborators

  • Rabin Medical Center

    collaborator OTHER

  • Assuta Medical Center

    lead OTHER

Principal Investigators

  • Michal Guindy, MD · Assuta Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03068520 on ClinicalTrials.gov